Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: Relationship with visceral adipose reduction

AIDS

Volumn 25, Issue 10, 2011, Pages 1281-1288

  Stanley, Takara L ^a   Falutz, Julian ^b   Mamputu, Jean Claude ^c   Soulban, Graziella ^c   Potvin, Diane ^c   Grinspoon, Steven K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

adiponectin; growth hormone releasing hormone; HIV; intraabdominal fat; plasminogen activator inhibitor 1; tesamorelin; tissue plasminogen activator

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN C; TESAMORELIN; TISSUE PLASMINOGEN ACTIVATOR;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ABDOMINAL FAT; ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; PLACEBOS; PLASMINOGEN ACTIVATOR INHIBITOR 1; TREATMENT OUTCOME;

EID: 79958817976     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328347f3f1     Document Type: Article

References (43)

1. Nguyen A, Calmy A, Schiffer V, Bernasconi E, Battegay M, Opravil M, et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 2008; 9:142-150.
2. Shlay JC, Bartsch G, Peng G, Wang J, Grunfeld C, Gibert CL, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007; 44:506-517. (Pubitemid 46594893)
3. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, Grunfield C. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008; 48:44-52. (Pubitemid 351600858)
4. Grunfeld C, Rimland D, Gibert CL, Powderly WG, Sidney S, Shlipak MG, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr 2007; 46:283-290. (Pubitemid 350287354)
5. Masia M, Padilla S, Garcia N, Jarrin I, Bernal E, Lopez N, et al. Endothelial function is impaired in HIV-infected patients with lipodystrophy. Antivir Ther 2010; 15:101-110.
6. Kosmiski LA, Bacchetti P, Kotler DP, Heymsfield SB, Lewis CE, Shlipak MG, et al. Relationship of fat distribution with adipo-kines in human immunodeficiency virus infection. J Clin En-docrinol Metab 2008; 93:216-224.
7. Guaraldi G, Stentarelli C, Zona S, Orlando G, Carli F, Ligabue G, et al. Lipodystrophy and antiretroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010; 208:222-227.
8. Guaraldi G, Zona S, Orlando G, Carli F, Giovanardi C, Garlassi E, et al. Visceral fat but not general adiposity is a predictor of cardiovascular disease in HIV-infected males. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2010.
9. Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, Lees RS, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005; 39:44-54. (Pubitemid 40617018)
10. Triant VA, Meigs JB, Grinspoon S. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268-273.
11. Hadigan C, Meigs JB, Rabe J, D'Agostino RB, Wilson PW, Lipinska I, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86:939-943. (Pubitemid 32207521)
12. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly study. Circulation 2005; 112:3080-3087. (Pubitemid 43113439)
13. Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost 2007; 5:1795-1800. (Pubitemid 47288932)
14. Lowe GD, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2004; 25:252-259. (Pubitemid 38235163)
15. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007; 357:2359-2370. (Pubitemid 350223390)
16. Beauregard C, Utz AL, Schaub AE, Nachtigall L, Biller BM, Miller KK, Klibanski A. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008; 93:2063-2071. (Pubitemid 351831516)
17. Johansson JO, Landin K, Johannsson G, Tengborn L, Bengtsson BA. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost 1996; 76:422-428. (Pubitemid 26373538)
18. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008; 22:1719-1728.
19. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres JP. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996; 64:685-693. (Pubitemid 26398268)
20. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 1982; 36:172-177. (Pubitemid 12000247)
21. Hunter GR, Snyder SW, Kekes-Szabo T, Nicholson C, Berland L. Intra-abdominal adipose tissue values associated with risk of possessing elevated blood lipids and blood pressure. Obes Res 1994; 2:563-568.
22. Williams MJ, Hunter GR, Kekes-Szabo T, Trueth MS, Snyder S, Berland L, Blaudeau T. Intra-abdominal adipose tissue cut-points related to elevated cardiovascular risk in women. Int J Obes Relat Metab Disord 1996; 20:613-617. (Pubitemid 26237719)
23. Onat A, Avci GS, Barlan MM, Uyarel H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004; 28:1018-1025. (Pubitemid 38998708)
24. Ryan AS, Berman DM, Nicklas BJ, Sinha M, Gingerich RL, Meneilly GS, et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care 2003; 26:2383-2388. (Pubitemid 36993330)
25. He G, Andersen O, Haugaard SB, Lihn AS, Pedersen SB, Madsbad S, Richelsen B. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines. Eur J Clin Invest 2005; 35:583-590. (Pubitemid 41243302)
26. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 1998; 22:312-317. (Pubitemid 28138436)
27. Triant V, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endo Metab 2007; 92:2506-2512. (Pubitemid 47037350)
28. Gorog DA. Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J Am Coll Cardiol 2010; 55:2701-2709.
29. Pradhan AD, LaCroix AZ, Langer RD, Trevisan M, Lewis CE, Hsia JA, et al. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women. Circulation 2004; 110:292-300. (Pubitemid 38955498)
30. Gram J, Bladbjerg EM, Moller L, Sjol A, Jespersen J. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study. J Intern Med 2000; 247:205-212. (Pubitemid 30108354)
31. Sam S, Haffner S, Davidson MH, D'Agostino RB, Feinstein S, Kondos G, et al. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 2009; 32:932-937.
32. He G, Andersen O, Haugaard SB, Lihn AS, Pedersen SB, Madsbad S, Richelsen B. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines. Eur J Clin Invest 2005; 35:583-590. (Pubitemid 41243302)
33. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretro-viral therapy. J Acquir Immune Defic Syndr 2002; 29:441-449. (Pubitemid 34456334)
34. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730-1737. (Pubitemid 38489895)
35. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007; 165:164-174. (Pubitemid 46096378)
36. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23:85-89. (Pubitemid 36091630)
37. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11:1096-1103. (Pubitemid 41486832)
38. Kumada M, Kihara S, Ouchi N, Ouchi N, Ouchi N, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109:2046-2049. (Pubitemid 38620209)
39. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003; 88:627-636. (Pubitemid 36207802)
40. Tong Q, Sankale JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, et al. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 2003; 88:1559-1564. (Pubitemid 36623370)
41. Perry A, Wang X, Goldberg R, Ross R, Jackson L. The relationship between cardiometabolic and hemostatic variables: influence of race. Metabolism 2008; 57:200-206.
42. Lutsey PL, Cushman M, Steffen LM, Green D, Barr RG, Her-rington D, et al. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost 2006; 4:2629-2635. (Pubitemid 44741559)
43. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab 2011; 96:150-158.